Following the Company’s Fix, Fund, Propel
approach, Mr. Dais’s hire strengthens financial expertise,
leadership, and oversight, along with continuing Navidea’s focus on
advancing innovative technology to market
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced the hiring of Craig A. Dais, CPA in the position of Chief
Financial Officer (CFO), reporting directly to the Company’s Chief
Medical Officer. Mr. Dais’s hiring aligns with the Company’s stated
objectives and its Fix, Fund, Propel approach to advancing
innovative technology to market.
Financial Expertise, Leadership, and Oversight
Craig A. Dais’s hiring in the role of CFO, strengthens the
Company’s financial expertise and oversight, supported by G2G
Ventures as Executive Consultants, with demonstrated expertise in
accounting, financial modeling, capital development, and strong
growth-oriented leadership within private and publicly-held
organizations. In his role, he is responsible for overseeing all
aspects of Navidea’s financial success, including the preparation
of all financial statements, reporting and analysis, the active
management of the Company’s cash flows, and the development of
expert teams responsible for managing and tracking financial
activities.
“Craig is an active and experienced accounting and finance
leader with the ability to see both the details and the big
picture,” said Michael Blue, M.D., FACEP, Navidea’s Chief Medical
Officer. “He is a self-motivated leader with expertise in
developing strong teams that can help the Company grow by providing
insights, reporting, and financial acumen. His financial leadership
will help bring Navidea's technology and assets to the
forefront.”
Mr. Dais continues an impactful career as financial executive,
leader, and Certified Public Accountant, having served in various
roles of increasing responsibility over 30 years. His recent
experience includes serving as Chief Financial Officer at Colorado
Pain Care, LLC, (Fractional) Chief Financial Officer at Ascent CFO
Solutions, Chief Financial Officer at Duffy Crane & Hauling,
Vice President of Finance at Pendum LLC and other leadership
positions with public and private organizations. Craig began his
career in finance with KPMG Peat Marwick. Mr. Dais earned a
Bachelor of Science in Accounting, along with a Minor in Business,
from Metropolitan State University of Denver, and is (inactive
status) a Certified Public Accountant.
“I am thrilled to have the opportunity to join Navidea’s team as
Chief Financial Officer, and eager to get started,” said Mr. Dais.
“I believe my experience and career has led me to this role, and I
believe Navidea’s transformative technology can improve lives
around the world. My goal is to get to work using my experience to
make that happen.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, visit www.navidea.com.
About G2G Ventures
G2G Ventures is a Colorado-based private equity firm focused on
empowering organizations to reach their full potential through
investment and consulting services. Specializing in creating
long-term partnerships with trusted investors and established
businesses, G2G Ventures draws on strong internal balance sheet
liquidity, augmented by trusted investor capital, to craft bespoke
capital solutions which include private equity investment, venture
capital participation, and mezzanine debt options. Beyond financial
investment, G2G Ventures provides accretive consulting services to
help clarify strategic goals and key performance indicators (KPIs),
evolve financial processes, and enhance operational effectiveness.
To learn more about how G2G Ventures is a growth partner for
enduring business, connect with our team.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727546541/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. G2G Ventures - Executive Consultant Theodore Gerbick Chief
Marketing Officer tgerbick@g2g.ventures
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 12 2024 まで 1 2025
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 1 2024 まで 1 2025
